Drug Profile
Avapritinib - Blueprint Medicines
Alternative Names: AYVAKIT; AYVAKYT; BLU-285; CS 3007; TaijihuaLatest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Blueprint Medicines
- Developer Blueprint Medicines; CStone Pharmaceuticals; Neopharm Ltd
- Class 2 ring heterocyclic compounds; Amines; Antineoplastics; Pyrazoles; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules; Triazines
- Mechanism of Action Platelet derived growth factor alpha receptor antagonists; Proto oncogene protein c-kit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Gastrointestinal stromal tumours; Systemic mastocytosis
- Phase II Haematological malignancies
- Phase I/II Solid tumours
Most Recent Events
- 26 Feb 2024 Updated efficacy and adverse events data from the phase II PIONEER trial in Systemic Mastocytosis presented at the The American Academy of Allergy, Asthma & Immunology annual meeting (AAAAI annual meeting-2024)
- 08 Jan 2024 Blueprint Medicines announces intention to launch avapritinib for systemic mastocytosis in Europe in 2024
- 31 Dec 2023 Blueprint Medicines has patent pending for avapritinib worldwide